We believe the training programmes we plan to implement are greatly needed, and will further propel Malaysia into a leadership position for clinical development in ASEAN
Kuala Lumpur, MY (PRWEB) August 20, 2015
A Memorandum of Understanding (MoU) was signed between the International Medical University (IMU) and IndiPharm at the Putra World Trade Centre, Kuala Lumpur today in conjunction with the BioMalaysia Conference 2015. The exchange of MoU was witnessed by Yang Berhormat Datuk Wilfred Madius Tangau, Minister of Science, Technology and Innovation and Yang Berhormat Dato’ Sri Ahmad Shabery bin Cheek, Minister of Agriculture and Agro-based Industry.
The MoU reaffirms the commitment of IMU and IndiPharm to provide high quality and customised research training programmes to clinical staff engaged in the conduct of clinical trials. Through the programmes, both public and private sector personnel involved in the managing/monitoring of clinical research activities will be able to achieve a heightened level of work readiness, resulting in an increase in the number of clinical trials that can be conducted in Malaysia and ASEAN.
IMU’s Institute of Research, Development and Innovation (IRDI) will be in charge of this training programme with IndiPharm. This is in line with IRDI’s role which include providing research directions, research management and oversight, consultancy and services to various stakeholders.
“This collaboration complements IMU’s aspiration to be the leader in healthcare education. In addition to our existing healthcare programmes, we are excited to work with IndiPharm to train and enhance the skills of the workforce in clinical research management,” said Tan Sri Dato’ Dr Abu Bakar Suleiman, President, IMU.
This strategic collaboration will tap into IndiPharm’s extensive network and experience in the field of clinical research training. Mr. Jeffrey Scott Yablon, Vice President, Business Development & General Manager Asia, IndiPharm acknowledged the importance of creating differentiated training programmes for practical clinical research management and work readiness and added “We believe the training programmes we plan to implement are greatly needed, and will further propel Malaysia into a leadership position for clinical development in ASEAN.”
This concerted effort is in line with the government’s Economic Transformation Programme, which aims to create a supportive ecosystem to grow clinical research in Malaysia.
Public and private sectors interested in knowing more on this training programme are invited to join the IRDI’s Industry Talk on Clinical Research Training that will be held in October at the IMU Bukit Jalil campus.
For more information on the industry talk, please contact Ms. Lai Pei Kuan of IRDI, IMU at tel: +603-27317044 or email: irdi(AT)imu.edu.my
About International Medical University (IMU)
International Medical University (IMU) is Malaysia’s first and most established private medical and health sciences university with over 20 years of dedicated focus in healthcare education. Established in 1992, IMU pioneered the world’s first Partner Medical School programme and has since gained international recognition with over 30 world class university partners in Australia, New Zealand, United Kingdom, Canada, US, Ireland and China. IMU’s main campus is located at Bukit Jalil, Kuala Lumpur with branch clinical schools located in Seremban, Kuala Pilah, Batu Pahat and Kluang.
Committed to its brand promise, “Delivering the Future of Better Healthcare”, in 2010, IMU became be a fully integrated healthcare institution offering Education, Healthcare services in both medical and complimentary alternative medicine and Research to serve and improve the quality of lives.
IMU’s Institute of Research, Development and Innovation (IRDI)
IRDI is guided by a Joint Committee on Research and Ethics (IMU-JC) which consists of representatives from different fields including those from legal profession and religious group to evaluate research proposals. The IMU-JC has obtained accreditation from the National Pharmaceutical Control Bureau (NPCB), MOH to serve as one of the national Institutional Review Boards (IRB) for biomedical research and clinical trials. The four thrust areas identified under IRDI’s research and development programme are environmental and population health, bioactive molecules and drug discovery, cancer and stem cell research, and health professional education research. Under IRDI’s purview are also the School of Postgraduate Studies and the Commercialisation and Support arm.
For more information on IMU, visit http://www.imu.edu.my
IndiPharm (Malaysia) is a division of IndiPharm Inc. IndiPharm is a clinical development organisation, headquartered in the United States, with clinical and administrative operations in Malaysia and India. IndiPharm’s experienced management team, U.S.-based client services, strong global SOPs, well-trained medical and professional staff, combined with a deep understanding of the local culture and regulatory system, facilitates the delivery of cost effective, high quality clinical development services.
For additional information on IndiPharm visit http://www.indipharm.com